Wednesday’s Midday Stock Update: Conatus Pharmaceuticals (CNAT), Biocept Inc (BIOC), Chicago Bridge (CBI), Inovio Pharmaceuticals (INO), Himax Technologies (HIMX)

By Carrie Williams

So far Wednesday, January 24, NASDAQ is down -2.75% and the S&P is down -0.92%. Here are this morning’s most active stocks: Conatus Pharmaceuticals (NASDAQ:CNAT), Biocept Inc (NASDAQ:BIOC), Chicago Bridge (NYSE:CBI), Inovio Pharmaceuticals (NASDAQ:INO) and Himax Technologies (NASDAQ:HIMX).

Conatus Pharmaceuticals is down -11.86% in midday trading to $5.02. Shares opened today at $5.69. The company has a 52-week low of $3.88 and a 52-week high of $9.40. On the Street’s front, the average 12-month analyst price target for the stock is $17, marking a 198.77% potential upside from current levels. In a report issued on November 2, H.C. Wainwright analyst Ed Arce assigned a Buy rating on CNAT, with a price target of $17, which represents a potential upside of 199% from where the stock is currently trading.

Biocept Inc is down -11.65% in midday trading to $0.53. Shares opened today at $0.60. The company has a 52-week low of $0.53 and a 52-week high of $2.76.

Chicago Bridge is up 9.67% in midday trading to $21.55. Shares opened today at $19.65. The company has a 52-week low of $9.55 and a 52-week high of $36.15. On the Street’s front, the average 12-month analyst price target for the stock is $15.88, marking a -19.19% potential downside from current levels. In a report issued on January 3, Robert W. Baird analyst Andrew Wittmann reiterated a Hold rating on CBI, with a price target of $17, which reflects a potential downside of -13% from last closing price. Separately, on October 24, Deutsche Bank’s Chad Dillard maintained a Buy rating on the stock and has a price target of $20. In the last 30 days, insiders purchased $5,187 worth of CBI shares.

Inovio Pharmaceuticals is down -8.86% in midday trading to $5.04. Shares opened today at $5.53. The company has a 52-week low of $4.09 and a 52-week high of $9.86. On the Street’s front, the average 12-month analyst price target for the stock is $12.5, marking a 126.04% potential upside from current levels. In a report released yesterday, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on INO, with a price target of $13, which represents a potential upside of 135% from where the stock is currently trading.

Himax Technologies is down -8.24% in midday trading to $8.41. Shares opened today at $9.16. The company has a 52-week low of $4.88 and a 52-week high of $13.95. On the Street’s front, the average 12-month analyst price target for the stock is $13.17, marking a 43.78% potential upside from current levels. In a report issued on January 11, Credit Suisse analyst Jerry Su maintained a Buy rating on HIMX, with a price target of $15, which represents a potential upside of 64% from where the stock is currently trading. Separately, on December 5, Rosenblatt Securities’ Jun Zhang reiterated a Sell rating on the stock and has a price target of $6.